CapsoVision (CV)

Market Price (9/21/2026): $7.02 | Market Cap: $350.6 MilSector: Health Care | Industry: Life Sciences Tools & Services

CapsoVision (CV)

Market Price (9/21/2026): $7.02
Market Cap: $350.6 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -117%, 3Y Excs Rtn is -152%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -30 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -217%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 10%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -200%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -201%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 23.03

Key risks
CV key risks include [1] significant financial strain and a heightened bankruptcy risk, Show more.

0	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Remote Patient Monitoring, Show more.
1	Weak multi-year price returns 2Y Excs Rtn is -117%, 3Y Excs Rtn is -152%
2	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -30 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -217%
3	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 10%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -200%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -201%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
6	Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 23.03
7	Key risks CV key risks include [1] significant financial strain and a heightened bankruptcy risk, Show more.

CV in ETFs

Weight = CV's share of each fund

VTI0.00%

IWM0.01%

IWO0.01%

VTWO0.01%

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	9/21/26	2025	2024	2023
Share Price			$7.02	$10.69	$35.26	$35.26
Mkt Cap ($ Mil)			350.6	501.0	1,634.1	-
+ Debt ($ Mil)			0.7	0.9	1.2	0.0
- Cash ($ Mil)			9.1	10.1	9.3	0.0
TEV ($ Mil)			342.2	501.9	1,635.3
Valuation Ratios
P/S	18.2	23.7	25.2	37.0	139.0	-
P/EBIT	—	—	-11.6	-19.6	-82.0	-
P/E	—	—	-11.8	-19.8	-82.1	-
P/FCF	—	—	-12.6	-21.8	-80.7	-
Sector Ratios (* = sector average)
P/S *			4.1	4.0	3.9	4.2
P/EBIT *			-1.9	-1.7	-1.4	-1.5
P/E *			-1.7	-1.8	-1.6	-1.8
P/FCF *			-2.0	-1.8	-1.4	-1.6

FYE: 12/31	Forward FYE		Now
	2027	2026	9/21/26
Share Price			$7.02
Mkt Cap ($ Mil)			350.6
+ Debt ($ Mil)			0.7
- Cash ($ Mil)			9.1
TEV ($ Mil)			342.2
Valuation Ratios
P/S	18.2	23.7	25.2
P/EBIT	—	—	-11.6
P/E	—	—	-11.8
P/FCF	—	—	-12.6
Sector Ratios (* = sector average)
P/S *			4.1
P/EBIT *			-1.9
P/E *			-1.7
P/FCF *			-2.0

FYE: 12/31	CV [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$13.9 Mil	—
FY 2026 Sales	$14.8 Mil	—
FY 2027 Sales	$19.3 Mil	—
FY 2026 Sales Growth	6.4%	—
FY 2027 Sales Growth	30.4%	12.9%
EARNINGS
LTM Net Income (GAAP) [3]	$-29.8 Mil	—
FY 2026 Net Income (Non-GAAP)	$-26.4 Mil	—
FY 2027 Net Income (Non-GAAP)	$-21.1 Mil	—
FY 2027 Net Income Growth	—	18.1%
FY 2026 EPS (Non-GAAP)	$-0.56	—
FY 2027 EPS (Non-GAAP)	$-0.45	—
FY 2027 EPS Growth	—	—
VALUATION
FY 2026 P/S	23.7	1.6
FY 2027 P/S	18.2	—
FY 2026 P/E	—	7.4
FY 2027 P/E	—	—

[1] CV forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

	CV	S&P 500
REVENUE GROWTH	GOOD
Rev LTM ($ Bil)	0.0
Rev Chg Q	9.9%	9.1%
Rev Chg LTM	11.0%	8.3%
Rev Chg 3Y Avg	11.0%	5.8%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-217.1%	18.6%
CFO/Rev LTM	-200.3%	21.8%
Net Inc Mgn	-214.7%	13.1%
VALUATION	VERY HIGH
P/S	25.2	3.1
P/CFO	-12.6	14.7
P/FCF	-12.6	19.1
P/E	-11.8	22.4
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.49	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
New Account Growth	75%	6302025	Link
Cumulative Patients for CapsoCam Plus®	over 143,000	6302025	Link

Price Chart

Upcoming
11/12/2026	Earnings Release	Rev: $3.0 Mil (E) EPS: $-0.15 (E)

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 9/18/2026

CapsoVision (CV) stock has remained largely at the same level since 5/31/2026 because of the following key factors:

1. Mixed Fiscal Q2 2026 Financial Results Offset Gains.

CapsoVision reported a 10% year-over-year revenue increase to $3.6 million in fiscal Q2 2026, driven by a 13% rise in CapsoCam Plus capsule volume. However, this positive revenue growth was largely offset by a decline in gross margin to 51% (from 55% in fiscal Q2 2025) and a significant widening of the net loss to $7.5 million, up from $4.6 million in the prior year period, primarily due to increased operating expenses from clinical trials and public company costs.

2. Strategic Product Pipeline Progress Balanced by Delays.

The company announced the international launch of its AI Highlights feature and continued advancement of CapsoCam Colon, with a planned 510(k) submission in fiscal Q4 2026. These developments signal potential future growth in its AI-enabled capsule endoscopy solutions. However, the CapsoCam Colon 510(k) submission was pushed back one quarter to fiscal Q4 2026, as additional subjects with significant polyps were needed, which may have tempered investor enthusiasm.

3. Capital Infusion Countered by Potential Dilution.

CapsoVision entered into a $100 million at-the-market equity program and, more recently, completed an $18 million direct stock offering in September 2026. This offering included substantial insider purchases, with Eliyahou Harari acquiring approximately $10 million in shares and Star One Global Capital Limited purchasing approximately $5 million. While these capital raises provide crucial funding for operations and development, the issuance of new equity shares carries the potential for dilution to existing shareholders.

4. Neutral Analyst Sentiment.

The consensus among Wall Street analysts for CapsoVision's stock has been a "Hold" rating as of September 2026, with an average price target of $9.50. This cautious outlook, combining "Buy" recommendations from some analysts with "Hold" and "Sell" ratings from others, indicates that the market is weighing the company's growth prospects against its financial challenges and uncertainties.

Show less

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -1.2% change in CV stock from 5/31/2026 to 9/20/2026 was primarily driven by a -5.0% change in the company's Shares Outstanding (Mil).

(LTM values as of)	5312026	9202026	Change
Stock Price ($)	6.78	6.70	-1.2%
Change Contribution By:
Total Revenues ($ Mil)	14	14	2.4%
P/S Multiple	23.7	24.1	1.5%
Shares Outstanding (Mil)	47	50	-5.0%
Cumulative Contribution			-1.2%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2026 to 9/20/2026

	Return	Correlation
CV	-1.2%
Market (SPY)	0.9%	15.7%
Sector (XLV)	12.7%	0.2%

Fundamental Drivers

The 22.0% change in CV stock from 2/28/2026 to 9/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	2282026	9202026	Change
Stock Price ($)	5.49	6.70	22.0%
Change Contribution By:
Total Revenues ($ Mil)	�	14	0.0%
P/S Multiple	�	24.1	0.0%
Shares Outstanding (Mil)	41	50	-18.3%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 9/20/2026

	Return	Correlation
CV	22.0%
Market (SPY)	11.6%	12.1%
Sector (XLV)	5.5%	2.1%

Fundamental Drivers

The 78.7% change in CV stock from 8/31/2025 to 9/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	8312025	9202026	Change
Stock Price ($)	3.75	6.70	78.7%
Change Contribution By:
Total Revenues ($ Mil)	�	14	0.0%
P/S Multiple	�	24.1	0.0%
Shares Outstanding (Mil)	41	50	-18.3%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 9/20/2026

	Return	Correlation
CV	78.7%
Market (SPY)	19.4%	12.1%
Sector (XLV)	24.1%	13.9%

Fundamental Drivers

null
null

Market Drivers

8/31/2023 to 9/20/2026

	Return	Correlation
CV	-81.0%
Market (SPY)	75.6%	9.8%
Sector (XLV)	32.3%	10.1%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
CV Return	0%	0%	0%	0%	-70%	-41%	-82%
Peers Return	19%	-20%	-8%	-19%	37%	8%	5%
S&P 500 Return	27%	-19%	24%	23%	16%	12%	103%
Monthly Win Rates [3]
CV Win Rate	0%	0%	0%	0%	33%	44%
Peers Win Rate	60%	50%	48%	42%	54%	58%
S&P 500 Win Rate	75%	42%	67%	75%	67%	44%
Max Drawdowns [4]
CV Max Drawdown	0%	0%	0%	0%	-90%	-57%
Peers Max Drawdown	-29%	-44%	-49%	-37%	-37%	-43%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, TECH, ATEC, CERS, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)

Event	CV	S&P 500
2010 Eurozone Sovereign Debt Crisis / Flash Crash
% Loss	-12.6%	-15.4%
% Gain to Breakeven	14.4%	18.2%
Time to Breakeven	190 days	125 days
2008-2009 Global Financial Crisis
% Loss	-47.4%	-53.4%
% Gain to Breakeven	90.2%	114.4%
Time to Breakeven	922 days	1085 days
Summer 2007 Credit Crunch
% Loss	-18.7%	-8.6%
% Gain to Breakeven	23.0%	9.5%
Time to Breakeven	1375 days	47 days

Compare to A, TECH, ATEC, CERS, FRNM

In The Past

CapsoVision's stock fell -0.7% during the 2011 US Debt Ceiling Crisis & European Contagion. Such a loss loss requires a 0.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	CV	S&P 500
2008-2009 Global Financial Crisis
% Loss	-47.4%	-53.4%
% Gain to Breakeven	90.2%	114.4%
Time to Breakeven	922 days	1085 days

Compare to A, TECH, ATEC, CERS, FRNM

In The Past

CapsoVision's stock fell -0.7% during the 2011 US Debt Ceiling Crisis & European Contagion. Such a loss loss requires a 0.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About CapsoVision (CV)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

CapsoVision (CV) is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) solutions for diagnosing abnormalities of the gastrointestinal (GI) tract. Its flagship product is the CapsoCam Plus, a single-use, wire-free capsule endoscopy system designed for panoramic visualization of the small-bowel mucosa. This system, which includes the physical capsule and proprietary CapsoCloud/CapsoView software, allows healthcare providers to identify conditions such as obscure GI bleeding and Crohn's disease without the need for patient-worn data recorders, offering clinicians a flexible, zero-capex workflow. CapsoVision primarily serves gastroenterologists in clinics and hospitals, selling directly in the U.S. and both directly and through qualified distributors in international markets like France, Germany, and Canada.

The company has demonstrated consistent growth, with revenues increasing from $9.8 million in 2023 to $11.8 million in 2024, representing 21% year-over-year growth, primarily driven by increasing CapsoCam Plus unit sales. CapsoVision is expanding its technology with the upcoming integration of AI-assisted reading for CapsoCam Plus, targeting FDA clearance and commercialization by late 2025 to reduce review time for clinicians. Looking ahead, the company is developing CapsoCam Colon, a pipeline product that incorporates AI for automatic polyp detection and a 3D sensor for size measurement, with revenues for its second generation targeted for the U.S. in late 2026 and the EU in early 2027. Longer-term, CapsoVision plans to adapt its panoramic imaging for new GI indications such as esophageal varices and pancreatic cancer, with feasibility studies beginning in 2025 and 2026.

AI Analysis | Feedback

It's like a high-tech, disposable GoPro for your digestive system, with AI to help doctors quickly find problems.
Think of it as the 'Cologuard of visual GI diagnostics,' offering a less invasive way for doctors to inspect your insides with a smart camera pill, instead of traditional procedures.

AI Analysis | Feedback

CapsoCam Plus System: A capsule endoscopy solution, including a single-use capsule and viewing software (CapsoCloud/CapsoView), designed for panoramic visualization and diagnosis of small-bowel abnormalities.
CapsoCam Plus with AI Assisted Reading: An upcoming update to the CapsoCam Plus system that will incorporate AI to detect and highlight suspected abnormalities, aiming to reduce clinician review time.
CapsoCam Colon (Pipeline): A developing capsule endoscope product designed to automatically detect polyps and measure their size in the colon using integrated AI and a 3D sensor.
Future CapsoCam Applications (Pipeline): Longer-term adaptations of the CapsoCam platform being explored for new GI medical indications such as esophageal conditions and pancreatic cancer.

AI Analysis | Feedback

CapsoVision (CV) sells primarily to other companies and medical institutions. Based on the provided information, the company's major customers fall into the following categories:

Hospitals
Clinics (specifically those where gastroenterologists practice)
Qualified exclusive distributors (for international sales)

The provided text does not name specific customer companies or their symbols.

AI Analysis | Feedback

null

AI Analysis | Feedback

Kang-Huai (Johnny) Wang, President, Chief Executive Officer and Director

Mr. Wang is a co-founder of CapsoVision, and has served as President and Chief Executive Officer since November 2024. He previously served as CapsoVision's President and Chief Technology Officer from October 2006 to October 2024. Prior to joining CapsoVision, he was Vice President of Engineering for ESS Technology and also served as Chief Executive Officer and co-founder of Divio, Inc., a video processing chip design company. Mr. Wang was also a Design Manager for C-Cube Microsystem and held various engineering roles in the semiconductor industry.

David Michael Garcia, Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer

Mr. Garcia serves as Senior Vice President, Finance at CapsoVision, overseeing the company's financial strategy, planning, and operations, and brings over 20 years of financial leadership experience. Before joining CapsoVision, he was Vice President of Financial Planning and Analysis at Matterport, Inc. from 2020 to 2025, where he played a key role in the company's initial public offering and its subsequent acquisition. His prior experience includes senior finance roles at View, Inc., IntelePeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte.

Douglas Atkinson, Senior Vice President of Global Sales

Mr. Atkinson joined CapsoVision as Head of Global Sales in October 2016. Before CapsoVision, he was Director of Sales for MedTech Micro-Fixation from May 2015 to October 2016. He also served as Regional Sales Director at Medtronic PLC from January 2005 to April 2015, and as Regional Director of Sales and National Accounts at Stryker Corporation from May 1995 to December 2004, where he was recognized for multiple sales leadership and revenue growth awards.

AI Analysis | Feedback

Key Risks to CapsoVision (CV)

Going Concern and Liquidity Risk: CapsoVision has a history of operating losses, an accumulated deficit, and a stated substantial doubt about its ability to continue as a going concern, which could adversely impact its ability to fund growth strategies and meet cash and liquidity needs.
Regulatory Clearance Delays or Failure: The company's ability to commercialize its updated CapsoCam Plus with AI-assisted reading technology and its new pipeline product, CapsoCam Colon, is dependent on receiving timely FDA 510(k) clearances and EU CE Marks, which may be delayed or not obtained at all, impacting future revenue generation.
Dependence on a Single Product and Market Competition: All current revenues are derived from the CapsoCam Plus for small bowel visualization, making the company highly dependent on the continued success and growth of this single product. Its ability to grow is also subject to intense competition from existing FDA-cleared products and established market players.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

CapsoVision (CV) anticipates several key drivers for future revenue growth over the next 2-3 years:

Expanded Sales of CapsoCam Plus System: The company plans to further grow its existing sales and marketing team to increase sales of its CapsoCam Plus small-bowel capsule system, building on its consistent revenue growth and high customer retention rate of approximately 90% in 2024. This includes strengthening its market presence, as evidenced by establishing a direct sales team in Germany in 2023.
Commercialization of AI-Assisted CapsoCam Plus: CapsoVision is updating its CapsoCam Plus with self-developed AI-assisted reading technology. The company targets FDA 510(k) and EU submissions in the second half of 2025, with clearance of the updated capsule and subsequent commercialization by the end of 2025. This enhancement is expected to make capsule endoscopy more financially attractive to practices by reducing video review time.
Launch of CapsoCam Colon System: To expand beyond small-bowel sales, CapsoVision is developing CapsoCam Colon, a new capsule endoscope for colon visualization, incorporating AI for polyp detection and a 3D sensor for polyp-size measurement. The company targets U.S. revenues for its second-generation CapsoCam Colon system beginning in the second half of 2026, following FDA 510(k) clearance, and EU revenues in early 2027, after receiving a CE Mark.

AI Analysis | Feedback

null

Interactive Breakdown

null

null

Better Bets vs. CapsoVision (CV)

null

Peer Outperformance in Life Sciences Tools & Services

CV has trailed 59% of its 108 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.

Share of Life Sciences Tools & Services constituents that CV has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.

75%

of 126 industry peers · 41.4% return

23%

of 116 industry peers · -81.0% return

41%

of 108 industry peers · -81.0% return

No Life Sciences Tools & Services peer with a comparable growth profile has beaten CV by more than 20pp over 5Y.

Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is CV's own industry. Use this to see which corners of the sector have carried the returns.

Industry	Names	1Y med	3Y med	5Y med	Top 3 by 5Y
Health Care Distributors	6	16.2%	43.2%	90.1%	CAH 392% · MCK 346% · COR 168%
Managed Health Care	8	40.4%	-5.3%	2.3%	OSCR 84% · HQY 56% · ELV 17%
Health Care Services	20	21.1%	37.6%	-0.3%	HIMS 239% · RDNT 173% · DGX 76%
Health Care Facilities	24	6.0%	6.5%	-4.5%	NHC 271% · THC 261% · ENSG 129%
Health Care Equipment	50	-2.7%	-0.2%	-21.1%	POCI 11050% · UFPT 341% · GKOS 222%
Pharmaceuticals	62	-10.5%	14.8%	-38.6%	LQDA 2472% · INDV 1099% · ETON 1051%
Health Care Supplies	12	14.1%	-8.9%	-39.7%	LNTH 287% · HAE 54% · MMSI 20%
Life Sciences Tools & Services ←	109	4.3%	-11.3%	-68.4%	SNWV 1757% · MEDP 231% · NTRA 199%
Health Care Technology	21	-25.8%	-52.6%	-79.2%	SPOK 68% · HSTM 3% · VEEV -13%
Biotechnology	364	0.6%	-21.7%	-79.4%	CELZ 1280% · DNTH 1221% · ELVN 1069%

Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	CapsoVision Stock Pre-Market (-11%) : FDA 510(k) Submission for AI Module	12/30/2026
2	CapsoVision Stock Surges 161%, With A 7-Day Winning Spree	12/12/2025
3	CapsoVision Stock Rockets 114% With 6-Day Winning Streak	12/11/2025
4	CapsoVision Stock Jump Looks Great, But How Secure Is That Gain?	10/17/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to CV.

null

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
GEMI	Gemini Space Station	0.7	31.2%	-41.4%
FWDI	Forward Industries	0.7	24.2%	16.5%
SECZ	Securitize	1.6	21.6%	-11.7%
MSTR	Strategy	54.3	16.4%	1.3%
ABTC	American Bitcoin	0.7	14.4%	-60.4%
MARA	MARA	5.1	13.7%	47.4%
PS	Pershing Square	19.9	13.7%	106.6%
SBET	Sharplink	2.0	13.2%	4.6%
SGML	Sigma Lithium	1.1	12.3%	-24.4%
BTGO	BitGo	0.9	11.8%	-59.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
XENE	Xenon Pharmaceuticals	4.0	-30.7%	-11.3%
KDK	Kodiak AI	0.6	-14.4%	-70.0%
ADBT	Advasa	0.1	-13.6%	-98.0%
HELP	Helus Pharma	0.6	-11.8%	60.0%
GTN-A	Gray Media	0.5	-11.4%	-56.2%
CRD-B	Crawford	0.6	-8.8%	13.8%
SMR	NuScale Power	3.0	-8.5%	-41.6%
RSI	Rush Street Interactive	2.6	-7.7%	19.9%
BTU	Peabody Energy	3.1	-7.4%	-14.4%
TNGX	Tango Therapeutics	3.3	-7.4%	145.5%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
SDGR	Schrodinger	2.2	52.6%	62.3%
PS	Pershing Square	19.9	32.3%	106.6%
BBNX	Beta Bionics	1.0	32.1%	-28.2%
TEM	Tempus AI	14.0	31.9%	31.8%
SECZ	Securitize	1.6	31.3%	-11.7%
TWST	Twist Bioscience	10.4	31.3%	426.5%
EMAT	Evolution Metals & Technologies	2.5	30.5%	-81.1%
GEMI	Gemini Space Station	0.7	30.3%	-41.4%
RUM	Rumble	2.6	26.8%	43.8%
ALMR	Alamar Biosciences	2.0	25.0%	58.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
ADBT	Advasa	0.1	-47.1%	-98.0%
SWMR	Swarmer	0.4	-39.4%	-22.6%
ALHC	Alignment Healthcare	1.7	-33.8%	-57.7%
XENE	Xenon Pharmaceuticals	4.0	-32.2%	-11.3%
FLNC	Fluence Energy	1.0	-26.3%	-63.0%
ENVA	Enova International	4.3	-21.8%	11.1%
VYX	NCR Voyix	0.9	-21.2%	-33.9%
ARWR	Arrowhead Pharmaceuticals	9.5	-19.8%	0.1%
DMRA	Damora Therapeutics	1.4	-19.6%	-1.8%
IONS	Ionis Pharmaceuticals	7.4	-18.0%	-43.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SECZ	Securitize	1.6	80.1%	-11.7%
FWDI	Forward Industries	0.7	55.9%	16.5%
PURR	Hyperliquid Strategies	1.7	50.1%	295.8%
GEMI	Gemini Space Station	0.7	47.8%	-41.4%
MSTR	Strategy	54.3	47.6%	1.3%
SMTC	Semtech	17.2	47.6%	151.1%
CVI	CVR Energy	5.4	46.3%	112.4%
SDGR	Schrodinger	2.2	46.2%	62.3%
EMAT	Evolution Metals & Technologies	2.5	41.1%	-81.1%
ACVA	ACV Auctions	1.8	40.3%	30.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
ALMS	Alumis	1.0	-67.6%	-20.4%
IESC	IES	12.8	-47.5%	-17.2%
SWMR	Swarmer	0.4	-46.9%	-22.6%
RARE	Ultragenyx Pharmaceutical	1.5	-44.7%	-36.9%
TTAN	ServiceTitan	5.2	-42.1%	-48.3%
FLNC	Fluence Energy	1.0	-39.4%	-63.0%
KRMN	Karman	4.7	-38.6%	-51.1%
XENE	Xenon Pharmaceuticals	4.0	-36.2%	-11.3%
DYN	Dyne Therapeutics	2.8	-36.1%	-12.5%
DKS	Dick's Sporting Goods	10.7	-36.1%	-37.5%

Peer Comparisons

Peers to compare with:

Financials

	CV	A	TECH	ATEC	CERS	FRNM	Median
Name	CapsoVis.	Agilent .	Bio-Tech.	Alphatec	Cerus	Freenome
Mkt Price	6.70	156.47	72.37	10.18	2.65	17.11	13.64
Mkt Cap	0.3	44.1	11.3	1.6	0.5	-	1.6
Rev LTM	14	7,372	1,215	815	222	-	815
Op Inc LTM	-30	1,639	273	-39	-2	-	-2
FCF LTM	-28	1,267	263	-6	-2	-	-2
FCF 3Y Avg	-	1,257	252	-83	-8	-	122
CFO LTM	-28	1,609	292	57	2	-	57
CFO 3Y Avg	-	1,630	293	-7	-5	-	144

Growth & Margins

	CV	A	TECH	ATEC	CERS	FRNM	Median
Name	CapsoVis.	Agilent .	Bio-Tech.	Alphatec	Cerus	Freenome
Rev Chg LTM	11.0%	8.6%	-0.4%	19.5%	15.1%	-	11.0%
Rev Chg 3Y Avg	-	2.0%	2.3%	24.6%	13.0%	-	7.7%
Rev Chg Q	9.9%	8.1%	1.3%	15.1%	9.5%	-	9.5%
QoQ Delta Rev Chg LTM	2.4%	1.9%	0.3%	3.6%	2.3%	-	2.3%
Op Inc Chg LTM	-47.3%	13.5%	12.3%	59.1%	86.2%	-	13.5%
Op Inc Chg 3Y Avg	-	5.3%	-1.5%	29.6%	56.7%	-	17.4%
Op Mgn LTM	-217.1%	22.2%	22.4%	-4.8%	-0.7%	-	-0.7%
Op Mgn 3Y Avg	-	22.1%	21.2%	-15.0%	-5.1%	-	8.0%
QoQ Delta Op Mgn LTM	-16.3%	0.7%	-1.9%	1.4%	0.7%	-	0.7%
CFO/Rev LTM	-200.3%	21.8%	24.0%	6.9%	1.1%	-	6.9%
CFO/Rev 3Y Avg	-	23.8%	24.5%	-2.6%	-3.2%	-	10.6%
FCF/Rev LTM	-200.8%	17.2%	21.7%	-0.7%	-0.8%	-	-0.7%
FCF/Rev 3Y Avg	-	18.3%	21.0%	-14.8%	-5.0%	-	6.7%

Valuation

	CV	A	TECH	ATEC	CERS	FRNM	Median
Name	CapsoVis.	Agilent .	Bio-Tech.	Alphatec	Cerus	Freenome
Mkt Cap	0.3	44.1	11.3	1.6	0.5	-	1.6
P/S	24.1	6.0	9.3	2.0	2.4	-	6.0
P/Op Inc	-11.1	26.9	41.5	-41.1	-328.7	-	-11.1
P/EBIT	-11.1	25.0	45.2	-26.0	433.9	-	25.0
P/E	-11.2	30.6	62.1	-14.5	-78.4	-	-11.2
P/CFO	-12.0	27.4	38.7	28.2	219.9	-	28.2
Total Yield	-8.9%	3.9%	2.1%	-6.9%	-1.3%	-	-1.3%
Dividend Yield	0.0%	0.6%	0.4%	0.0%	0.0%	-	0.0%
FCF Yield 3Y Avg	-	3.5%	2.6%	-5.5%	-2.5%	-	0.1%
D/E	0.0	0.1	0.0	0.4	0.1	-	0.1
Net D/E	-0.0	0.0	0.0	0.3	0.0	-	0.0

Returns

	CV	A	TECH	ATEC	CERS	FRNM	Median
Name	CapsoVis.	Agilent .	Bio-Tech.	Alphatec	Cerus	Freenome
1M Rtn	11.3%	-1.6%	0.2%	7.4%	-5.7%	23.9%	3.8%
3M Rtn	1.4%	23.4%	25.0%	15.6%	-1.9%	31.5%	19.5%
6M Rtn	-2.5%	41.2%	41.0%	-17.7%	54.1%	31.5%	36.3%
12M Rtn	41.4%	24.9%	36.9%	-34.5%	81.5%	31.5%	34.2%
3Y Rtn	-81.0%	45.9%	5.1%	-18.0%	75.5%	31.5%	18.3%
1M Excs Rtn	10.2%	1.4%	0.7%	5.2%	-6.3%	26.3%	3.3%
3M Excs Rtn	-0.6%	21.4%	23.0%	13.6%	-3.9%	29.5%	17.5%
6M Excs Rtn	-7.4%	24.8%	24.9%	-35.8%	34.8%	15.7%	20.3%
12M Excs Rtn	28.8%	8.6%	25.4%	-46.7%	99.5%	15.6%	20.5%
3Y Excs Rtn	-152.2%	-30.1%	-69.8%	-98.3%	-12.6%	-39.7%	-54.8%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Clinical Pipeline

null

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023
Period End	6/30/2026	12/31/2025	12/31/2024	12/31/2023
Filing Date	8/13/2026	3/26/2026	7/3/2025	7/3/2025
Key Financials
Total Revenue	14	14	12	10
Gross Profit	7	7	6	5
EBITDA	-30	-25	-19	-11
Operating Income	-30	-26	-20	-11
Net Income	-30	-25	-20	-11
EPS	-0.63	-1.03	-0.43	-0.29
Growth Rates
Total Revenue Growth	11.0%	15.3%	20.5%	-
EBITDA Growth	-48.3%	-28.6%	-77.0%	-
Operating Income Growth	-47.3%	-28.1%	-75.5%	-
Net Income Growth	-46.0%	-27.2%	-76.0%	-
Margins
Gross Margin	50.9%	52.9%	54.2%	56.3%
EBITDA Margin	-212.8%	-184.1%	-165.0%	-112.4%
Operating Income Margin	-217.1%	-188.3%	-169.4%	-116.3%
Net Income Margin	-214.7%	-186.8%	-169.3%	-115.9%
Cash & Debt
Total Cash	9	10	9	15
Total Debt	1	1	1	2
Net Debt / (Cash)	-8	-9	-8	-13
Cash Flows & CapEx
Net Cash from Operations	-28	-23	-20	-11
Total CapEx	-0	-0	-0	-1
Free Cash from Operations	-28	-23	-20	-12
Returns to Shareholders
Dividends	0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1
Period End	6/30/2026	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024
Filing Date	8/13/2026	5/14/2026	3/26/2026	11/13/2025	8/14/2025	7/3/2025	7/3/2025	11/13/2025	8/14/2025	7/3/2025
Key Financials Quarterly
Total Revenue	4	3	4	4	3	3	3	3	3	2
Ebitda	-7	-7	-7	-8	-5	-5	-5	-6	-5	-4
Operating Income	-8	-7	-7	-8	-5	-5	-5	-6	-5	-4
Net Income	-7	-7	-7	-8	-5	-5	-5	-6	-5	-4
EPS	-0.15	-0.15	-0.16	-0.17	-0.10	-0.12	-0.10	-0.14	-0.13	-0.10
Key Financials TTM
Total Revenue TTM	14	14	14	13	13	12	12	-	-	-
Ebitda TTM	-30	-27	-25	-22	-20	-21	-19	-	-	-
Operating Income TTM	-30	-27	-26	-23	-20	-21	-20	-	-	-
Net Income TTM	-30	-27	-25	-23	-20	-21	-20	-	-	-
Growth Rates Quarterly
Total Revenue Growth	9.9%	0.3%	13.5%	19.3%	16.6%	11.5%	-	-	-	-
EBITDA Growth	-64.6%	-32.4%	-62.5%	-38.9%	12.3%	-28.5%	-	-	-	-
Operating Income Growth	-63.0%	-31.8%	-61.1%	-38.2%	11.8%	-27.8%	-	-	-	-
Net Income Growth	-61.8%	-30.8%	-59.4%	-36.7%	12.2%	-28.0%	-	-	-	-
Margins Quarterly
EBITDA Margin	-203.8%	-248.7%	-186.8%	-222.6%	-136.0%	-188.5%	-130.4%	-191.2%	-180.9%	-163.6%
Operating Income Margin	-208.1%	-254.0%	-190.5%	-226.7%	-140.3%	-193.4%	-134.2%	-195.7%	-185.4%	-168.7%
Net Income Margin	-205.4%	-251.9%	-188.7%	-223.9%	-139.5%	-193.1%	-134.4%	-195.3%	-185.2%	-168.3%
Cash & Debt
Total Cash	9	18	10	18	1	4	9	-	-	-
Total Debt	1	1	1	1	2	1	1	0	0	0
Net Debt / (Cash)	-8	-17	-9	-17	1	-3	-8	-	-	-
Cash Flows Quarterly
FCF from Operations	-8	-6	-8	-6	-5	-5	-5	-7	-4	-4
Cash Flows TTM
FCF from Operations TTM	-28	-24	-23	-21	-22	-21	-20	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-17.3%	-17.1%	-18.7%	-21.1%	-787.0%	-15.2%	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-17.2%	-16.4%	-16.0%	-14.9%	-865.9%	-14.9%	-	-	-	-

Segment Financials

Revenue by Segment

$ Mil	2025	2024
Products (capsules and capsule reading devices)	13	11
Services (cloud-based video delivery and reading services)	1	1
Total	14	12

Price Behavior

Price Behavior

Market Price	$6.70
Market Cap ($ Bil)	0.3
First Trading Date	12/29/2006
Distance from 52W High	-53.5%
	50 Days	200 Days
DMA Price	$6.41	$5.12
DMA Trend	up	down
Distance from DMA	4.5%	30.8%
	3M	1YR
Volatility	66.1%	98.3%
Downside Capture	95.09	106.99
Upside Capture	92.23	129.44
Correlation (SPY)	11.4%	12.1%

CV Betas & Captures as of 8/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	2.79	0.87	0.77	0.69	0.93	0.14
Up Beta	0.59	-0.25	-0.83	-0.12	0.00	0.12
Down Beta	0.61	-1.06	0.98	1.04	1.02	0.24
Up Capture	268%	73%	89%	81%	160%	-5%
Bmk +ve Days	10	21	32	68	138	427
Stock +ve Days	7	19	30	58	121	142
Down Capture	672%	294%	161%	95%	104%	39%
Bmk -ve Days	11	21	32	59	113	324
Stock -ve Days	14	23	34	68	127	147

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with CV
CV	44.9%	97.7%	0.80	-
Sector ETF (XLV)	24.4%	16.1%	1.16	15.3%
Equity (SPY)	16.9%	12.9%	0.94	11.9%
Gold (GLD)	19.1%	29.3%	0.60	1.4%
Commodities (DBC)	46.3%	20.6%	1.73	-5.0%
Real Estate (VNQ)	4.9%	13.6%	0.10	7.9%
Bitcoin (BTCUSD)	-30.6%	44.3%	-0.70	1.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with CV
CV	9.9%	93.6%	0.82	-
Sector ETF (XLV)	6.4%	15.2%	0.24	11.2%
Equity (SPY)	12.9%	17.2%	0.57	11.1%
Gold (GLD)	19.1%	18.8%	0.83	1.1%
Commodities (DBC)	11.2%	19.5%	0.45	-2.3%
Real Estate (VNQ)	1.1%	18.8%	-0.05	6.3%
Bitcoin (BTCUSD)	12.5%	52.5%	0.42	2.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with CV
CV	4.8%	93.6%	0.82	-
Sector ETF (XLV)	10.6%	16.7%	0.51	11.2%
Equity (SPY)	15.1%	18.0%	0.72	11.1%
Gold (GLD)	12.1%	16.4%	0.61	1.1%
Commodities (DBC)	8.3%	18.1%	0.37	-2.3%
Real Estate (VNQ)	4.4%	20.7%	0.18	6.3%
Bitcoin (BTCUSD)	62.6%	66.2%	1.02	2.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	8312026
Short Interest: Shares Quantity	1.9 Mil
Short Interest: % Change Since 8152026	5.3%
Average Daily Volume	0.1 Mil
Days-to-Cover Short Interest	23.0 days
Basic Shares Quantity	49.9 Mil
Short % of Basic Shares	3.8%

Returns Analyses

	Title
0	CapsoVision Stock Jump Looks Great, But How Secure Is That Gain?

Earnings Returns History

Updated 9/18/2026

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/13/2026	-4.9%	-13.0%	-4.1%
5/14/2026	-11.6%	-7.3%	-1.0%
3/26/2026	-0.3%	-1.2%	-15.4%
11/13/2025	-9.7%	-6.0%	111.6%
8/14/2025	-4.2%	-1.0%	7.7%
SUMMARY STATS
# Positive	0	0	2
# Negative	5	5	3
Median Positive			59.7%
Median Negative	-4.9%	-6.0%	-4.1%
Max Positive			111.6%
Max Negative	-11.6%	-13.0%	-15.4%

Collapse to Preview

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/13/2026	-4.9%	-13.0%	-4.1%
5/14/2026	-11.6%	-7.3%	-1.0%
3/26/2026	-0.3%	-1.2%	-15.4%
11/13/2025	-9.7%	-6.0%	111.6%
8/14/2025	-4.2%	-1.0%	7.7%
SUMMARY STATS
# Positive	0	0	2
# Negative	5	5	3
Median Positive			59.7%
Median Negative	-4.9%	-6.0%	-4.1%
Max Positive			111.6%
Max Negative	-11.6%	-13.0%	-15.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
06/30/2026	08/13/2026	10-Q
03/31/2026	05/14/2026	10-Q
12/31/2025	03/26/2026	10-K
09/30/2025	11/13/2025	10-Q
06/30/2025	08/14/2025	10-Q
03/31/2025	07/03/2025	424B4

Recent Forward Guidance

Updated 8/14/2026

Latest: Q2 2026 Earnings Reported 8/13/2026

null

Insider Activity

Updated 9/18/2026

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Shen, Ching Hang	Star One Global Capital Limited	Buy	9182026	5.69	878,734	4,999,996	16,652,667	Form
2	Harari, Eliyahou ET AL	trust.	Buy	7202026	6.73	61,068	410,988	22,499,191	Form
3	Harari, Eliyahou ET AL	trust.	Buy	7102026	6.09	81,300	495,117	19,987,691	Form
4	Harari, Eliyahou ET AL	trust.	Buy	7022026	7.35	13,850	101,811	23,528,721	Form

Collapse to Preview

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Shen, Ching Hang	Star One Global Capital Limited	Buy	9182026	5.69	878,734	4,999,996	16,652,667	Form
2	Harari, Eliyahou ET AL	trust.	Buy	7202026	6.73	61,068	410,988	22,499,191	Form
3	Harari, Eliyahou ET AL	trust.	Buy	7102026	6.09	81,300	495,117	19,987,691	Form
4	Harari, Eliyahou ET AL	trust.	Buy	7022026	7.35	13,850	101,811	23,528,721	Form

Investor Activity (13F)

Updated

13F holdings as of

CV Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Status	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

Diversification Alternatives

How Is The Market Pricing CV?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What CV Makes & Who Pays

TTM figures based on

CV Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

CapsoVision — Investor Video Playlist

Products & Services

Dr. Farshid Sam Rahbar Shares How CapsoCam Plus® Enhances His Clinical Practice

CapsoVision · 2026-05-02

Products & Services

Dr. Nicholas Karyotakis: CapsoCam Plus® Reading Service

CapsoVision · 2025-06-30

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Life Sciences Tools & Services Resources

GenomeWeb

BioSpace

The Scientist

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 9/20/2026

CapsoVision (CV)

Market Price (9/21/2026): $7.02 | Market Cap: $350.6 MilSector: Health Care | Industry: Life Sciences Tools & Services

CapsoVision (CV)

Market Price (9/21/2026): $7.02Market Cap: $350.6 MilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

CV in ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About CapsoVision (CV)

Key Risks to CapsoVision (CV)

Interactive Breakdown

Better Bets vs. CapsoVision (CV)

Peer Outperformance in Life Sciences Tools & Services

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Clinical Pipeline

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance

Insider Activity

Investor Activity (13F)

CV Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

Market Price (9/21/2026): $7.02
Market Cap: $350.6 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services